Who
Nadim Ahmed
Director
Company insider
Files Form 4 as: Director, Disc Medicine; President and CEO, Cullinan Therapeutics; EVP and President, Hematology, Bristol-Myers Squibb; Pres., Global Hem. and Onc., Celgene Corp /de/.
In numbers
- Trades disclosed
- 139
- Buys
- 1
- Sells
- 10
- Bought
- $100K
- Sold
- $1.2M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 30 Jul 2018
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,176 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,176 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $196K13,515 at $14.47 | filing |
| 24 Feb 2026filed 25 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $196K13,515 at $14.47 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $223K16,381 at $13.62 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $223K16,381 at $13.62 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —828,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —828,000 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $99K9,922 at $10.01 | filing |
| 14 Jul 2025filed 16 Jul 2025 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K12,529 at $8.53 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 24 Dec 2024filed 27 Dec 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $100K8,400 at $11.87 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 26 Dec 2023filed 27 Dec 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $39K4,272 at $9.24 | filing |
| 28 Jun 2023filed 29 Jun 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,653759 at $11.40 | filing |
| 23 May 2023filed 24 May 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,469707 at $9.15 | filing |
| 25 Apr 2023filed 26 Apr 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,582716 at $10.59 | filing |
News
No headline names them, or the companies they trade most, lately.